Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: A 6-year population-based study from the nordic society of pediatric hematology and oncology

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 9, 2004, Pages 555-560

  Marky, Ildikó ^a,b   Björk, Olle ^a   Forestier, Erik ^a   Jónsson, Ólofur G ^a   Perkkiö, Mikko ^a   Schmiegelow, Kjeld ^a   Storm Mathiesen, Ingebjörg ^a   Gustafsson, Göran ^a  

^a Nordic Soc Pediat Hematol/Oncol ^*

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Child; Incidence; Non Hodgkin lymphoma; Outcome; Risk factors

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ARTICLE; BRAIN LYMPHOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX RATIO;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FINLAND; HUMANS; ICELAND; IMMUNOPHENOTYPING; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM STAGING; REMISSION INDUCTION; SCANDINAVIA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 4544353420     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000139772.98685.d2     Document Type: Article

References (9)

1. Márky I, Schmiegelow K, Perkkiö M, et al. Childhood non-Hodgkin's lymphoma in the five Nordic countries. A five-year populations-based study from the Nordic Society of Pediatric Hematology and Oncology. J Pediatr Hematol Oncol. 1995;17:163-166.
2. Harris NI, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
3. Murphy SB. Classification, staging and end result of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332-339.
4. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage: a report of the Berlin-Frankfurt-Münster group. J Clin Oncol. 1995;13:359-372.
5. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia. 2000;14:2267-2275.
6. Reiter A, Schrappe M, Tieman M. Successful treatment strategy for Ki-1 anaplastic large cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in 3 consecutive BFM Group studies. J Clin One. 1994; 12:899-908.
7. Nourusis MJ. SPSS statistical software. SPSS: Base and Advanced Statistics 10.0. Chicago: SPSS Inc., 1999.
8. Patte C, Auperin A, Michon J, et al. The Société Francaise d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370-3379.
9. Reiter A, Schrappe M, Ludvig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416-21.